Tuesday, June 25, 2019
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostics solutions, has signed a collaboration agreement with GSK to provide a combination of existing tests and development of customized tests to support some clinical trials of GSK antibiotics and new product development.
"We welcome this extension of utility and application of our testing and technology," said Colin Denver, chief executive officer of SpeeDx. "SpeeDx has demonstrated a commitment to improving patient care and our tests, currently used in clinical practice, support Resistance Guided Therapy, positively impacting cure rates and helping to minimize the spread of antimicrobial resistant infections."
